PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

ConditionMetastatic Prostate Cancer

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

AgeNot listed

SponsorNovartis Pharmaceuticals

About this trial

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer

Eligibility criteria

Qualifiers

Diagnosis of mPC

PSMA positive

Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

753 Participants

are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov